Grifols (GRFS) Total Non-Current Liabilities (2009 - 2025)
Grifols (GRFS) posted Total Non-Current Liabilities of $11.7 billion for Q4 2025, up 3.27% quarter-over-quarter from $11.4 billion in Q4 2024, and up 3.27% year-on-year from $11.4 billion in Q4 2024.
Grifols (GRFS) Total Non-Current Liabilities (2009 - 2025) Analysis & Trends
Grifols (GRFS) has reported Total Non-Current Liabilities for 16 consecutive years, with $11.7 billion the latest figure, recorded in Q4 2025.
- Total Non-Current Liabilities for Q4 2025 came in at $11.7 billion, up 3.27% year-over-year; the trailing twelve-month figure through Dec 2025 was $11.7 billion (up 3.27% YoY), and the FY2025 annual result was $11.7 billion, up 20873.57% from the prior year.
- Total Non-Current Liabilities was $11.7 billion for Q4 2025 at Grifols, up from $11.4 billion in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $12.0 billion in Q4 2023 and troughed at $9.7 billion in Q4 2021.
- Average Total Non-Current Liabilities over 5 years is $11.2 billion, with a median of $11.5 billion recorded in 2022.
- Year-over-year, Total Non-Current Liabilities grew 18.68% in 2022 and retreated 5.22% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $9.7 billion in 2021, then grew by 18.68% to $11.5 billion in 2022, then increased by 4.7% to $12.0 billion in 2023, then fell by 5.22% to $11.4 billion in 2024, then increased by 3.27% to $11.7 billion in 2025.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $11.7 billion in Q4 2025, $11.4 billion in Q4 2024, and $12.0 billion in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 48.74 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 119.22 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 109.01 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -34.06 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 75.17 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 100.00 Mn |
| 10 | Grifols | - | - | - | 11.75 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.75 Bn |
| Dec 31, 2024 | 11.37 Bn |
| Dec 31, 2023 | 12.00 Bn |
| Dec 31, 2022 | 11.46 Bn |
| Dec 31, 2021 | 9.66 Bn |
| Dec 31, 2020 | 8.61 Bn |
| Sep 30, 2020 | 8.52 Bn |
| Mar 31, 2020 | 8.12 Bn |
| Dec 31, 2019 | 8.11 Bn |
| Sep 30, 2019 | 8.18 Bn |
| Dec 31, 2018 | 7.45 Bn |
| Sep 30, 2018 | 7.61 Bn |
| Jun 30, 2018 | 7.69 Bn |
| Mar 31, 2018 | 8.96 Bn |
| Dec 31, 2017 | 7.43 Bn |
| Jun 30, 2017 | 7.29 Bn |
| Dec 31, 2016 | 5.75 Bn |
| Sep 30, 2016 | 5.70 Bn |
| Jun 30, 2016 | 5.82 Bn |
| Dec 31, 2015 | 5.75 Bn |